Berlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha ...

hepatocellular adenoma, and hepatic cysts. The affected population usually consists of young women. Clinical management should take into account the symptoms, history, hormonal status (present and ...

SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver ...

Pilatus Biosciences Publishes Preclinical Data in Cancer Discovery on PLT012 First-in-Class CD36-Targeting Antibody for Liver ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

HistoSonics is shopping for a potential buyer of its approach to destroying liver tumors with focused sound waves, according ...

NEW YORK - A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...